Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 827.9 INR 0.34% Market Closed
Market Cap: 148.3B INR

Natco Pharma Ltd
Investor Relations

Nestled in the bustling business corridors of Hyderabad, India, Natco Pharma Ltd. has cultivated a strong presence in the pharmaceutical industry over the decades. Founded in 1981, the company initially ventured into the local market, gradually establishing itself as a critical player through specialization in complex chemistry and niche therapeutic sectors. The company's primary focus is on the development and manufacturing of generic drugs, specifically in the oncology and neurology segments. In these high-stakes areas, Natco leverages its robust research and development capabilities to produce affordable alternatives to expensive branded medications, thereby ensuring access to critical treatments for broader populations.

Natco Pharma's business acumen extends beyond merely producing generics. It is adept at capitalizing on patent expirations, quickly launching generics and biosimilars in both domestic and international markets. The company has strategically focused operations in markets such as the United States and Europe, where it partners with local distributors to reach end-users. Through a combination of manufacturing efficiencies and strategic partnerships, Natco is able to maintain competitive pricing, thus enhancing its market penetration and revenue generation. Its integrated business model, combining in-house R&D, manufacturing, and distribution, ensures that Natco remains a formidable player, bridging the gap between complex pharmaceuticals and cost-effective healthcare solutions.

Show more
Loading
NATCOPHARM
BSE Sensex 30

Earnings Calls

2025 Q4
May 9, 2025
Show Transcript
Previous
Next
Strong sales growth and positive outlook for Jindal Stainless.
2025 Q4
May 9, 2025

In Q4 FY '25, Jindal Stainless reported a 9% year-over-year sales volume increase driven by robust domestic demand, particularly from the railway and automotive sectors. Despite challenges in global markets, the company remains optimistic, projecting a 9-10% volume growth for FY '26 and a substantial rise in export sales by 25-30%. EBITDA per ton is guided at INR 19,000 to 21,000 for the year, reflecting an expected recovery. Ongoing investments, including a stake in M1xchange and expansion in Maharashtra, support future growth while maintaining a stable balance sheet with net debt at INR 4,005 crores.

Show Full Analysis

Management

Mr. Venkaiah Chowdary Nannapaneni M. Pharm, MS.
MD & Chairman
No Bio Available
Mr. Rajeev Nannapaneni
CEO & Vice Chairman
No Bio Available
Mr. S. V. V. N. Appa Rao
Chief Financial Officer
No Bio Available
Dr. Donthineni Linga Rao M.D.
President of Technical Affairs & Whole Time Director
No Bio Available
Mr. Chekuri Venkat Ramesh C.S.
Company Secretary & Compliance Officer
No Bio Available
Mr. Potluri Sivaramakrishna Prasad
Executive VP of Corporate Engineering Services & Whole Time Director
No Bio Available
Dr. Pavan Ganapati Bhat
Executive VP of Technical Operations & Director
No Bio Available
Nadella Malleswara Rao
VP & Head of Operations
No Bio Available
N. Sadasiva Rao
Executive Vice President of Corporate Affairs, Legal, Secretarial & Estate Management
No Bio Available
James Rajakumar
Vice President of Marketing & Sales - Domestic
No Bio Available

Contacts

Address
TELANGANA
Hyderabad
Natco House, Road No 2, Banjara Hills
Contacts